Webinar Wednesdays is planned to be held on the last Wednesday of each month - starting on Wednesday, April 24th (at 1PM Eastern) with the first webinar on the increasing prevalence of non-small cell lung cancer in never smokers and how drug candidate LP-300 and the Harmonic Clinical Trial is looking to change these outcomes..

周三的网络研讨会计划在每个月的最后一个星期三举行，从4月24日星期三（东部时间下午1点）开始，第一次网络研讨会将讨论从不吸烟者中非小细胞肺癌患病率的增加以及候选药物LP-300和Harmonic临床试验如何改变这些结果。。

The second Webinar Wednesdays will focus on drug development needs in an area of critical patient need, pancreatic cancer, and how drug candidate LP-184 can address tumors with certain genomic and mutational profiles – this webinar is planned for Wednesday, May 29th (at 1pm Eastern).

周三举行的第二次网络研讨会将重点讨论关键患者需求领域的药物开发需求，胰腺癌，以及候选药物LP-184如何解决具有某些基因组和突变特征的肿瘤-本次网络研讨会计划于5月29日（星期三）（东部时间下午1点）举行。

The webinars will feature world-class collaborators and researchers, such as Dr. Joseph Treat and Dr. Igor Astsaturov of Fox Chase Cancer Center and Dr. Marc Chamberlain of Starlight Therapeutics.

网络研讨会将邀请世界级的合作者和研究人员参加，如福克斯蔡斯癌症中心的约瑟夫·特雷特博士和伊戈尔·阿斯塔佐夫博士以及星光治疗公司的马克·张伯伦博士。

DALLAS--(BUSINESS WIRE)--

达拉斯--（商业新闻）--

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, announced today that – the company has launched Webinar Wednesdays, a webinar series that focuses on areas of high oncology drug development interest with leading physicians, scientists and Lantern collaborators in drug development and artificial intelligence.

Lantern Pharma Inc.（纳斯达克股票代码：LTRN）是一家人工智能（“AI”）公司，利用其专有的RADR®AI和机器学习（“ML”）平台以及多个临床阶段药物计划开发靶向和转化性癌症治疗，今天宣布，该公司已于周三推出网络研讨会，这是一个网络研讨会系列，重点关注与领先的医生，科学家和Lantern药物开发和人工智能合作者高度关注的肿瘤药物开发领域。

The series begins today, Wednesday, April 24, 2024, and is planned to be held on the last Wednesday of each month..

该系列节目于2024年4月24日（星期三）开始，计划于每个月的最后一个星期三举行。。

Each webinar will feature a presentation from a Lantern collaborator, advisor, or researchers followed by a live Q&A. These sessions provide a deep dive into the company’s research, collaborations, clinical trials and expected goals for the drug or AI development initiatives. The series kicks off today, Wednesday April 24, focusing on LP-300, a novel therapeutic for the treatment of non-small cell lung cancer in never-smokers presented by Dr.

每个网络研讨会都将有一个灯笼合作者、顾问或研究人员的演讲，然后是现场问答。这些会议将深入了解该公司的研究、合作、临床试验以及药物或人工智能开发计划的预期目标。该系列于今天（4月24日星期三）开始，重点关注LP-300，这是一种治疗从不吸烟者非小细胞肺癌的新型治疗药物。

Joseph Treat. Next month Dr. Igor Astsaturov will share his experience, and approach for the treatment of pancreatic cancer and other solid tumors and how synthetically lethal drug candidate, LP-184 fits into an increasingly biomarker driven paradigm for cancer treatments..

约瑟夫·特里特。下个月，Igor Aststatov博士将分享他的经验，治疗胰腺癌和其他实体瘤的方法，以及合成致死候选药物LP-184如何适应日益生物标志物驱动的癌症治疗范例。。

Future topics will include Starlight Therapeutics, a subsidiary of Lantern Pharma that focuses on central nervous system and brain cancers, and updates on RADAR®, Lantern’s proprietary AI and ML platform for oncology drug development and computational onco-biology at-scale.

未来的主题将包括Starlight Therapeutics，Lantern Pharma的子公司，专注于中枢神经系统和脑癌，以及RADAR®的更新，Lantern专有的AI和ML平台用于肿瘤药物开发和大规模计算肿瘤生物学。

————

————

April’s Webinar Wednesday

四月周三的网络研讨会

April 24, 2024 – 1:00pm Eastern

2024年4月24日–东部时间下午1:00

“LP-300 in Never-Smokers with Non-small Cell Lung Cancer”

“不吸烟者非小细胞肺癌中的LP-300”

Register here: https://bit.ly/3vO117s

在此处注册：https://bit.ly/3vO117s

Join Joseph Treat, MD and Reggie Ewesuedo, MD to explore lung cancer in never-smokers, defining its uniqueness, challenges that patients are facing, and the successes and future of the Harmonic™ Phase 2 clinical trial for LP-300 in never-smokers with non-small cell lung cancer.

加入医学博士Joseph Treat和医学博士Reggie Ewsuedo，探索从不吸烟者的肺癌，定义其独特性，患者面临的挑战，以及针对LP-300的Harmonic™2期临床试验在不吸烟者中的成功与未来。非小细胞肺癌。

Presentation: Joseph Treat, MD

演讲：医学博士Joseph Treat

Joseph Treat, MD, is principal investigator of the Harmonic™ study in the United States and a leading expert in lung malignancies, including non-small cell lung cancer in never-smokers. Dr. Treat is a Professor in the Department of Hematology and Oncology, Vice Chair of Education, and Medical Director of Ambulatory Care at Fox Chase Cancer Center..

医学博士JosephTreat是美国Harmonic™研究的首席研究员，也是包括不吸烟者的非小细胞肺癌在内的肺部恶性肿瘤的领先专家。Treat博士是Fox Chase癌症中心血液学和肿瘤学系教授、教育副主席和门诊医疗主任。。

Q&A: Reggie Ewesuedo, MD

问答：Reggie Ewesuedo，医学博士

Reggie Ewesuedo, MD, is Vice President of Clinical Development at Lantern Pharma. Dr. Ewesuedo has more than 20 years of expertise in drug development research activities and has served in clinical research lead capacities at The Ohio State University, AstraZeneca, Genzyme, Sanofi, Pfizer, Tesaro/GlaxoSmithKline, and Kymera..

医学博士ReggieEwsuedo是Lantern Pharma临床开发副总裁。Ewesuedo博士在药物开发研究活动方面拥有20多年的专业知识，并曾在俄亥俄州立大学，阿斯利康，Genzyme，赛诺菲，辉瑞，特萨罗/葛兰素史克和Kymera担任临床研究领导。。

May’s Webinar Wednesday

五月网络研讨会周三

May 29, 2024 – 1:00pm Eastern

2024年5月29日-东部时间下午1:00

“LP-184 in Pancreatic Cancer and Other Solid Tumors”

“LP-184在胰腺癌和其他实体瘤中的作用”

Register here: https://bit.ly/3U9NizL

在此处注册：https://bit.ly/3U9NizL

Join Igor Astsaturov, MD and Kishor Bhatia, PhD to explore the science of pancreatic cancer and other solid tumors, challenges around diagnosis and treatments of the disease, and LP-184 as a promising agent for these tumors with ongoing Phase 1 trial and multiple preclinical validations.

加入医学博士Igor Astsathov和博士Kishor Bhatia，探索胰腺癌和其他实体瘤的科学，围绕疾病诊断和治疗的挑战，以及LP-184作为这些肿瘤的有希望的药物，正在进行1期临床试验和多次临床前验证。

Presentation: Igor Astsaturov, MD

演讲：医学博士Igor Astsathov

Igor Astsaturov, MD is a leading expert in pancreatic cancer collaborating with Lantern Pharma on the LP-184 clinical trial. Dr. Astsaturov is an Associate Professor in the Department of Hematology/Oncology, Co-Director of the Marvin & Concetta Greenburg Pancreatic Cancer Institute, and Inaugural Holder of the Paul F.

医学博士Igor Aststatov是胰腺癌领域的领先专家，与Lantern Pharma合作进行LP-184临床试验。Astsathov博士是血液学/肿瘤学系的副教授，马文与康塞塔·格林伯格胰腺癌研究所的联合主任，也是Paul F。

Engstrom Professorship in Oncology..

肿瘤学教授。。

Q&A: Kishor Bhatia, PhD

问答：Kishor Bhatia博士

Kishor Bhatia, PhD, is Chief Scientific Officer at Lantern Pharma. Kishor brings more than 40 years of experience in cancer research, which has included roles such as Director of the Children’s Cancer Center Riyadh and Director of the Office of AIDS Malignancy Program at the National Cancer Institute (NCI)..

KishorBhatia博士是Lantern Pharma的首席科学官。Kishor在癌症研究方面拥有40多年的经验，其中包括利雅得儿童癌症中心主任和国家癌症研究所（NCI）艾滋病恶性肿瘤项目办公室主任。。

_________________

_________________

About Lantern Pharma:

关于Lantern Pharma：

Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 60 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development.

Lantern Pharma（纳斯达克股票代码：LTRN）是一家AI公司，它改变了肿瘤药物发现和开发的成本、速度和时间表。我们专有的人工智能和机器学习（ML）平台RADR®利用了600多亿个以肿瘤学为中心的数据点和200多个先进的ML算法库，帮助解决肿瘤学药物开发中数十亿美元的现实问题。

By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate (ADC) program.

通过利用人工智能的力量以及世界级科学顾问和合作者的投入，我们加速了跨越多种癌症适应症（包括实体瘤和血癌）以及抗体-药物偶联物（ADC）计划的不断增长的治疗渠道的发展。

On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0 - 2.5 million per program..

平均而言，我们新开发的药物计划在2-3年内从最初的人工智能见解发展为首次人体临床试验，每个计划约为100万至250万美元。。

Our lead development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials. We have also established a wholly-owned subsidiary, Starlight Therapeutics, to focus exclusively on the clinical execution of our promising therapies for CNS and brain cancers, many of which have no effective treatment options.

我们的潜在客户开发计划包括2期临床计划和多个1期临床试验。我们还成立了一家全资子公司Starlight Therapeutics，专门专注于我们有前途的中枢神经系统和脑癌治疗的临床实施，其中许多没有有效的治疗选择。

Our AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD and have the potential to provide life-changing therapies to hundreds of thousands of cancer patients across the world..

据估计，我们由人工智能驱动的创新产品候选渠道的年市场潜力合计超过150亿美元，并有可能为全球数十万癌症患者提供改变生活的疗法。。

Please find more information at:

有关更多信息，请访问：

Website: www.lanternpharma.com

网址：www.lanternpharma.com

LinkedIn: https://www.linkedin.com/company/lanternpharma/

LinkedIn: https://www.linkedin.com/company/lanternpharma/

X: @lanternpharma

X： @lanternpharma

Forward-looking Statements:

前瞻性声明：

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others.

本新闻稿包含经修订的《1933年证券法》第27A节和经修订的《1934年证券交易法》第21E节所指的前瞻性声明。这些前瞻性报表除其他事项外，还包括与以下事项有关的报表：未来事件或我们未来的财务业绩；我们的RADR®平台在识别可能对候选药物有反应的候选药物和患者人群方面的潜在优势；我们推进候选药物和抗体-药物偶联物（ADC）开发计划发展的战略计划；关于我们候选药物和ADC开发计划的开发时间的估计；关于临床试验时间和患者登记的期望和估计；我们的内部药物发现计划的研究和开发工作以及利用我们的RADR®平台来简化药物开发过程；我们打算利用人工智能，机器学习和基因组数据来简化和改变肿瘤药物发现和开发的速度，风险和成本，并确定可能对候选药物产生反应的患者人群；关于患者人群，潜在市场和潜在市场规模的估计；我们对候选药物的销售估计以及我们发现和开发候选药物的计划，并通过自己或与他人合作推进这些候选药物来最大限度地发挥其商业潜力。

Any statements that are not statements of historical fact (including, without limitation, statements that use words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' .

任何不属于历史事实陈述的陈述（包括但不限于使用诸如“预期”、“相信”、“沉思”、“可能”、“估计”、“预期”、“打算”、“寻求”、“可能”、“可能”、“可能”、“计划”、“潜力”、“预测”、“项目”、“目标”等词语的陈述）。

Lantern Pharma Disclosure Channels to Disseminate Information:

Lantern Pharma信息披露渠道：

Lantern Pharma’s investors and others should note that we announce material information to the public about our company and its technologies, clinical developments, licensing matters and other matters through a variety of means, including Lantern Pharma’s website, press releases, SEC filings, digital newsletters, and social media, in order to achieve broad, non-exclusionary distribution of information to the public.

Lantern Pharma的投资者和其他人应注意，我们通过各种方式（包括Lantern Pharma的网站、新闻稿、SEC文件、数字时事通讯和社交媒体）向公众公布有关公司及其技术、临床发展、许可事项和其他事项的重要信息，以便向公众广泛、非排他性地传播信息。

We encourage our investors and others to review the information we make public in the locations above as such information could be deemed to be material information. Please note that this list may be updated from time to time..

我们鼓励我们的投资者和其他人审查我们在上述地点公布的信息，因为这些信息可能被视为重大信息。请注意，此列表可能会不时更新。。

View source version on businesswire.com: https://www.businesswire.com/news/home/20240424562625/en/

在businesswire.com上查看源版本：https://www.businesswire.com/news/home/20240424562625/en/

Investor Relations – IR@lanternpharma.com

投资者关系-IR@lanternpharma.com

Source: Lantern Pharma Inc.Released April 24, 2024

资料来源：Lantern Pharma Inc.于2024年4月24日发布